Boothbay Fund Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
– Sell
-114,200
Closed -$2.77M – 2025
2025
Q3
$2.77M Buy
114,200
+41,900
+58% +$745K 0.04% 486
2025
Q2
$950K Buy
+72,300
New +$916K 0.02% 697

Boothbay Fund Management's CNTA Position: Q2 2026 in Review

Boothbay Fund Management sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 39,656 shares — an estimated $1.58M sold.

Boothbay Fund Management first reported a position in CNTA in Q4 2024 and held it in 6 quarters. The position peaked at $1.58M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

  • Boothbay Fund Management reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 39,656 Centessa Pharmaceuticals shares in Q2 2026, an estimated $1.58M.
  • Boothbay Fund Management first reported a position in Centessa Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • Boothbay Fund Management's Centessa Pharmaceuticals position peaked at $1.58M in Q1 2026.
  • 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.